We see important biological differences in the ability of phosphorylatable vs. non-phosphorylatable CARM1 to support leukemia cell proliferation and demonstrate the therapeutic relevance of targeting both JAK2-V617F and CARM1 in JAK2-V617F-positive cells. Here, CARM1 is linked to leukemia.